CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis

We investigated a patient who developed multiple sclerosis (MS) during treatment with the CTLA4‐blocking antibody ipilimumab for metastatic melanoma. Initially he showed subclinical magnetic resonance imaging (MRI) changes (radiologically isolated syndrome). Two courses of ipilimumab were each follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerdes, Lisa Ann, Held, Kathrin, Beltrán, Eduardo, Berking, Carola, Prinz, Jörg C., Junker, Andreas, Tietze, Julia K., Ertl‐Wagner, Birgit, Straube, Andreas, Kümpfel, Tania, Dornmair, Klaus, Hohlfeld, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129566/
https://www.ncbi.nlm.nih.gov/pubmed/27351142
http://dx.doi.org/10.1002/ana.24715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129566/
https://www.ncbi.nlm.nih.gov/pubmed/27351142
http://dx.doi.org/10.1002/ana.24715

Ejemplares similares